格隆汇11月27日丨石四药集团(02005.HK)公告，集团的维生素A棕榈酸酯已获中国国家药品监督管理局 批准登记成为在上市制剂使用的原料药。维生素A棕榈酸酯主要用于脂溶性维生素注射液，补充维生 素。 ...

石四药集团(02005)公布，该集团的维生素A棕榈酸酯已获中国国家药品监督管理局批准登记成为在上市 制剂使用的原料药。维生素A棕榈酸酯主要用于脂溶性维生素注射液，补充维生素。 ...

石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的維生素 A 棕櫚酸酯已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原 料藥。維生素 A 棕櫚酸酯主要用於脂溶性維生素注射液，補充維生素。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 香港，二零二五年十一月二十七日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 ...

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 石四药集团 | 曲继广 | 好仓 | 12.24 亿股 | 12.26 亿股 | 41.54%(最新) | | (02005) | | | | | 41.46%(前次) | | 石四药集团 | China Pharmaceutical | 好仓 | 8.86 亿股 | 8.89 亿股 | 30.11%(最新) | | (02005) | Company Limited | | | | 30.03%(前次) | 智通财经APP获悉，石四药集团(02005)于2025年11月27日进行了最新股东权益披露。 ...

Core Viewpoint - 石四药集团 has received production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1: Company Developments - 石四药集团's stock rose nearly 3%, currently up 2.68% at HKD 3.06, with a trading volume of HKD 16.01 million [1] - The Indobufene Tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also be used to prevent thrombosis during hemodialysis [1] Group 2: Market Insights - Indobufene Tablets, developed by an Italian company, have become a substitute for aspirin for patients who are intolerant to it [1] - According to the MoShang Pharmaceutical Database, the total hospital sales of Indobufene Tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to exceed 1.9 billion in 2024, with a year-on-year increase of 37.47%, and over 1.1 billion in the first half of 2025, with a year-on-year increase of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]

Core Viewpoint - Stone Four Pharmaceutical Group has seen a nearly 3% increase in stock price following the announcement of obtaining production registration for Indobufene tablets from the National Medical Products Administration of China, indicating a significant development in their product pipeline [1] Company Summary - Stone Four Pharmaceutical Group's stock rose by 2.68% to HKD 3.06, with a trading volume of HKD 16.01 million [1] - The company has received approval for Indobufene tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Product Summary - Indobufene tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also prevent thrombosis during hemodialysis [1] - Developed by an Italian company, Indobufene has become a substitute for aspirin in patients who are intolerant to it [1] Market Summary - According to the MoSheng Pharmaceutical Database, the total hospital sales of Indobufene tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to surpass 1.9 billion in 2024, reflecting a year-on-year increase of 37.47%, and exceed 1.1 billion in the first half of 2025, with a year-on-year growth of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]

| 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 石四药集团 | 曲继广 | 好仓 | 12.22 亿股 | 12.24 亿股 | 41.46%(最新) | | (02005) | | | | | 41.39%(前次) | | 石药集团(01093) | 蔡东晨 | 好仓 | 28.87 亿股 | 28.97 亿股 | 25.14%(最新) | | | | | | | 25.06%(前次) | 智通财经APP获悉，石四药集团(02005)、石药集团(01093)于2025年11月26日进行了最新股东权益披 露。 备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 ...

石四药集团回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.11.25 | 200.00 | 3.000 | 2.960 | 596.56 | | 2025.10.30 | 500.00 | 3.130 | 3.030 | 1541.46 | | 2025.10.21 | 210.00 | 2.920 | 2.880 | 608.13 | | 2025.10.14 | 210.00 | 2.940 | 2.870 | 609.08 | | 2025.10.10 | 150.00 | 2.970 | 2.940 | 442.95 | | 2025.10.08 | 200.00 | 2.880 | 2.850 | 572.66 | | 2025.10.06 | 300.00 | 2.930 | 2.880 | 869.89 | | 2025.09.23 | 500.00 | 2.960 | 2.920 | 1467.48 | | 2025.09.12 | 90.00 | ...

智通财经APP讯，石四药集团(02005)发布公告，于2025年11月25日，该公司斥资596.56万港元回购200 万股。 （原标题：石四药集团(02005)11月25日斥资596.56万港元回购200万股） ...

格隆汇11月25日丨石四药集团(02005.HK)发布公告，2025年11月25日耗资596.56万港元回购200万股， 回购价格每股2.96-3港元。 ...